The American Journal of Gastroenterology

Castle Biosciences Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
General Health, Medical Devices, Other Health, Health, Medical Supplies, Adjustment, Laboratory, EAC, Metastasis, Innovation, The American Journal of Gastroenterology, Physician, Esophageal cancer, New York State Department of Health, EBITDA, Net, News, Cancer, GAAP, BE, Acquisition, Memorial Sloan Kettering Cancer Center, Sentinel lymph node, Workplace, Purpose, Risk, Compensation, Webcast, LGD, Question and Answer, Depreciation, HGD, Depression, American Journal, Table, Investment, Patient, Compensation and benefits, Pharmaceutical industry, Lithium, Video game, Film industry, Cryptocurrency, Clothing, Birth control, Medical imaging, Real estate

Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:

Key Points: 
  • Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:
    DecisionDx®-Melanoma test reports delivered in the quarter were 8,559, compared to 7,354 in the third quarter of 2022, an increase of 16%.
  • DecisionDx®-SCC test reports delivered in the quarter were 2,820, compared to 1,636 in the third quarter of 2022, an increase of 72%.
  • MyPath® Melanoma test reports delivered in the quarter were 1,011, compared to 834 MyPath Melanoma and DiffDx®-Melanoma aggregate test reports in the third quarter of 2022, an increase of 21%.
  • Castle Biosciences will hold a conference call on Thursday, Nov. 2, 2023, at 4:30 p.m. Eastern time to discuss its third quarter 2023 results and provide a corporate update.

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
Monday, October 23, 2023
Research, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, General Health, Science, Education, Patient, American College, UC, The American Journal of Gastroenterology, LANCL2, ACG, Lipid metabolism, Safety, American College of Gastroenterology, Ulcerative colitis, Abstract, New Drug Application, Biomarker, NDA, Neutrophil, American Journal, Gene expression, CD, Pharmaceutical industry, Medical device, Medical imaging

Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).

Key Points: 
  • Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).
  • Title: Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Crohn’s Disease.
  • Title: Transcriptional Analysis of Colonic Biopsies from Patients with Ulcerative Colitis Treated with Omilancor.
  • Additionally, the peer-reviewed accepted abstracts will be published verbatim in a special supplement to the October 2023 issue of The American Journal of Gastroenterology.

Biomerica Reports Fiscal 2023 Year End Results

Retrieved on: 
Friday, August 25, 2023
SAB, Migraine, Osteoarthritis, Helicobacter pylori, LDT, Mayo Clinic, CRC, Hereditary diffuse gastric cancer, The American Journal of Gastroenterology, Intellectual property, EZ, Clinical and Translational Gastroenterology, COVID-19, CVS, Coronavirus Scientific Advisory Board, Completeness, Large intestine, Ulcerative colitis, Gastroesophageal reflux disease, Colorectal cancer, CLIA, American Journal, Phlebotomy, Patient, Physician, IBS, National accounts, Rome, FDA, Stomach, Pharmaceutical industry, Walmart, Gastroenterology

Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022.

Key Points: 
  • Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022.
  • Net loss was $7.1 million for fiscal 2023 compared to a net loss of $4.6 million for fiscal 2022.
  • The decrease in sales for fiscal 2023 was related to the Company’s decrease in sales of COVID-19 antigen tests in fiscal 2023 compared to the prior fiscal year.
  • Sales revenues excluding Covid test sales increased by 15% for fiscal 2023 compared to fiscal 2022.

New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

Retrieved on: 
Monday, August 7, 2023
Science, Biometrics, Biotechnology, Research, Oncology, Health, Genetics, Other Health, University, LGD, Marie Cassidy, SURF, Pathology, Radiofrequency ablation, Gastrointestinal Endoscopy, Cancer, SOC, Incidence, BE, American Journal, The American Journal of Gastroenterology, Dysplasia, Patient, Standard of care, Risk, Surveillance, Mortality, Nursing, Pharmaceutical industry, IND

The full study is available here .

Key Points: 
  • The full study is available here .
  • The study results showed the following:
    Using TissueCypher test results to guide patient management decisions, in conjunction with the standard of care (SOC), significantly increased the likelihood of patients receiving appropriate management per their known outcome.
  • Overall, the study results suggest that TissueCypher may be used to standardize the management of BE patients with NDBE, IND and LGD.
  • Use of the TissueCypher test may also improve health outcomes by identifying patients at a low risk of progression who can avoid unnecessary therapy and be managed using surveillance alone.

United Digestive Physician Elected ACG Governor of Georgia

Retrieved on: 
Thursday, July 27, 2023
Indiana University, University, International, Gastroenterology, UD, The American Journal of Gastroenterology, Indiana University School of Medicine, Editorial Board at The Wall Street Journal, Public policy, Liver transplantation, Syphon Filter, American Journal, Patient, Physician, Medical Center, Associate, Member, American College of Gastroenterology, American College, UCLA, Health, MPH, ACG, Boston Medical Center, United Nations Credentials Committee, Nursing, MD

ATLANTA, July 27, 2023 /PRNewswire/ -- Hetal A. Karsan, MD, an Atlanta Gastroenterology Associates physician, has been elected as the newest Governor of Georgia for the American College of Gastroenterology (ACG). Dr. Karsan will serve a term of three years.

Key Points: 
  • ATLANTA, July 27, 2023 /PRNewswire/ -- Hetal A. Karsan, MD, an Atlanta Gastroenterology Associates physician, has been elected as the newest Governor of Georgia for the American College of Gastroenterology (ACG).
  • He is currently the Chair of the Credentials Committee for Memberships and the International Governor for the American College of Gastroenterology.
  • As the newly elected Governor of Georgia, Dr. Karsan plans to advance the ACG's public policy agenda directly to federal policymakers and help remove barriers that directly affect patient care.
  • "I am honored to have been elected as ACG's Governor of Georgia.

Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms

Retrieved on: 
Thursday, July 20, 2023
The American Journal of Gastroenterology, Cannabinoid, OTCQB, Research, American Journal, IBS, American College of Gastroenterology, American College, Health, Safety, Pharmaceutical industry, Dietary supplement

GOLDEN, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (“Panacea” or the “Company”), a plant-based natural health and wellness company, today announced it will be presenting its positive findings from open label clinical trial on the efficacy of its CBD/CBG Oral Solution to naturally treat irritable bowel syndrome (IBS) in adults.

Key Points: 
  • GOLDEN, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (“Panacea” or the “Company”), a plant-based natural health and wellness company, today announced it will be presenting its positive findings from open label clinical trial on the efficacy of its CBD/CBG Oral Solution to naturally treat irritable bowel syndrome (IBS) in adults.
  • “Our research identifies the safety and efficacy of an orally administered CBD/CBG tincture in adults with active symptoms of irritable bowel syndrome.
  • IBS affects 15% of the population of the U.S. and available conventional medical therapy is of limited efficacy.
  • The current version of Panacea’s CBD/CBG Tincture is available now at www.panacealife.com .

ChatGPT flunks American College of Gastroenterology exams, Feinstein Institutes report

Retrieved on: 
Monday, May 22, 2023
Science, Research, General Health, Health, Artificial Intelligence, Health Technology, Technology, Health Insurance, Education, The American Journal of Gastroenterology, LLM, ABIM, ChatGPT, Feinstein Institutes for Medical Research, Multimedia, Attention, OpenAI, Transformer, American Board of Commissioners for Foreign Missions, American Journal, MD, American Board of Internal Medicine, Internal medicine, Feinstein, Artificial intelligence, Paper, AI, American College of Gastroenterology, American College, ACG, Northwell Health, Book, Medical research, Nursing, Gastroenterology

To test its abilities and accuracy, investigators at The Feinstein Institutes for Medical Research asked the consumer-facing ChatGPT (Chat Generative Pre-trained Transformer, OpenAI) to take the 2021 and 2022 multiple-choice self-assessment tests for the American College of Gastroenterology.

Key Points: 
  • To test its abilities and accuracy, investigators at The Feinstein Institutes for Medical Research asked the consumer-facing ChatGPT (Chat Generative Pre-trained Transformer, OpenAI) to take the 2021 and 2022 multiple-choice self-assessment tests for the American College of Gastroenterology.
  • ChatGPT failed to make the grade, scoring 65.1 percent and 62.4 percent compared to the required 70 percent to pass the exams.
  • Full details of the study were published today in the American Journal of Gastroenterology .
  • View the full release here: https://www.businesswire.com/news/home/20230522005470/en/
    Dr. Arvind Trindade is the senior author on the paper which published in the American Journal of Gastroenterology.

CellMax Life Announces Expansion of GI Medical Advisory Board

Retrieved on: 
Tuesday, February 21, 2023
American College of Gastroenterology, Indiana University School of Medicine, Nuffield Department of Population Health, Health, American Society for Gastrointestinal Endoscopy, Department of Medicine – University of Pamplona, Colorectal cancer, Inflammatory Bowel Diseases, Gastrointestinal Endoscopy, New York University Grossman School of Medicine, Medicine, Population health, University, American Journal, Internal medicine, Gastroenterology, Research, Mortality, Senior, AGA, ASGE, Large intestine, Editor-in-chief, Stanford University School of Medicine, McGovern Medical School, ACG, AAS, The American Journal of Gastroenterology, UC San Diego Health, CRC, American College, NYU, Society, Johns Hopkins School of Medicine, Publishing, NYU Langone Health, Indiana University Health, MD, Pharmaceutical industry, Food delivery

SUNNYVALE, Calif., Feb. 21, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the expansion of its medical advisory board. The board is comprised of highly respected and experienced leaders in colorectal cancer screening and prevention.

Key Points: 
  • SUNNYVALE, Calif., Feb. 21, 2023 /PRNewswire-PRWeb/ -- CellMax Life , a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the expansion of its medical advisory board.
  • The board is comprised of highly respected and experienced leaders in colorectal cancer screening and prevention.
  • Dr. Rex co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer.
  • "I am excited to join CellMax's medical advisory board and to be with this highly accomplished group that brings significant experience in gastroenterology, and in particular, colorectal cancer screening and prevention," said Dr. Rex.

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Gastroesophageal reflux disease, Constipation, United States Air Force Scientific Advisory Board, Indigestion, The American Journal of Gastroenterology, Gastroparesis, Intestinal pseudo-obstruction, Lacy, Rome, Stomach, Mayo Clinic, IBS, Visceral pain, Gastrointestinal tract, Textbook, Patient, Diet, Research, Irritable bowel syndrome, Clinical and Translational Gastroenterology, Science, Book, Dysphagia, Esophageal achalasia, Esophageal motility disorder, Physician, American Journal, Medical device, Pharmaceutical industry, Gastroenterology

Dr. Lacy has authored over 225 peer reviewed articles

Key Points: 
  • Dr. Lacy has authored over 225 peer reviewed articles
    IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product.
  • I am honored to provide my expertise to Biomerica along with other esteemed members of the Scientific Advisory Board.”
    Dr. Lacy's areas of expertise include irritable bowel syndrome, gastroesophageal reflux disease, dysphagia, achalasia, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction and visceral pain.
  • Additionally, Dr. Lacy was the former co-Editor in Chief of the American Journal of Gastroenterology.
  • “Dr.

Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test

Retrieved on: 
Tuesday, December 20, 2022
Inflammatory bowel disease, Organization, American Cancer Society Cancer Action Network, CMS, Adenoma, Calendar year, Trial of the century, Patient, The American Journal of Gastroenterology, American Gastroenterological Association, ACA, Affordable Care Act, Exact sciences, AGA, COVID-19, National Comprehensive Cancer Network, MPPA, CY, Risk, Colonoscopy, Privacy, Medicare, Blood, FDA, Colorectal cancer, American Cancer Society, DNA, PJ, The New England Journal of Medicine, American Journal, CRC, Centers for Medicare & Medicaid Services, Cancer, Policy, Health insurance, Pharmaceutical industry, Exact Sciences (company)

These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient.

Key Points: 
  • These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient.
  • There are data which show that when we increase access to colorectal cancer screening and help navigate patients needing a follow-up colonoscopy after a non-invasive screening test, those disparities are greatly reduced."
  • However, patients have noted that out-of-pocket costs for colonoscopy following positive stool-based testing, remain a barrier to increasing CRC screening rates.
  • "[iii] For most Medicare beneficiaries and commercially-insured patients, no cost sharing will be incurred for either a Cologuard test or a follow-on colonoscopy.